Table 1.
Role of miRNAs in regulation of DOX and TXL responses in lung tumor cells
| miRNA | Target | Samples | Results | Clinical application | Study | Year |
|---|---|---|---|---|---|---|
| Signaling pathways | ||||||
| miR-7 | EGFR |
20 T 20N* A549, H1395, 95C and 95D cell lines |
Increased Paclitaxel sensitivity | Diagnosis | Liu [39] | 2014 |
| miR-4262 | PTEN |
20 T 20N A549, H1299, A549/PTX and H1299/PTX cell lines Xenograft model |
Increased Paclitaxel resistance | Diagnosis | Sun [42] | 2019 |
| miR-181a | PTEN | A549, A549/PTX, and A549/DDP cell lines | Increased Paclitaxel resistance | Diagnosis | Li [43] | 2015 |
| miR-4715-5p | RAC1 |
25 T 25N A549, Calu1, H1299, and HOP62 cell lines Xenograft model |
Increased Paclitaxel sensitivity | Diagnosis | Yang [52] | 2019 |
| miR-9600 | STAT3 |
144 T 20N A549, SPC-A-1, H1299, SK-MES-1, NCI-H520, 95D and 16HBE cell lines Xenograft model |
Increased Paclitaxel sensitivity | Diagnosis and prognosis | Sun [57] | 2016 |
| miR-1247-3p | STAT5A |
162 T 162N NCI-H1299, NCI-H1395, A549, NCL-H460, PG49, NCI-H1993 cell lines Xenograft model |
Increased Doxorubicin sensitivity | Diagnosis and prognosis | Lin [59] | 2022 |
| miR-337-3p | RAP1A | H1155, H1299, H1819, H1993, HCC2935, and HCC515 cell lines | Increased Paclitaxel sensitivity | Diagnosis | Du [67] | 2012 |
| miR-34c | NOTCH1 |
30 T 30N A549, H1299, and 293 T cell lines Xenograft model |
Increased Paclitaxel sensitivity | Diagnosis | Yang [69] | 2020 |
| Transcription factors and DNA binding proteins | ||||||
| miR-138 | ZEB2 | A549, NCI-H23, A549/ADM and NCI-H23/ADM cell lines | Increased Doxorubicin sensitivity | Diagnosis | Jin [73] | 2016 |
| miR-194-5p | HIF-1 | H460 and A549 cell lines | Increased Doxorubicin sensitivity | Diagnosis | Xia [75] | 2021 |
| mR-608 | TFAP4 |
37 T 37N 96 T serum 136N serum A549 and HCC4006 cell lines |
Increased Doxorubicin sensitivity | Diagnosis | Wang [81] | 2019 |
| miR-935 | SOX7 |
30 T 30N A549 cell line |
Increased Paclitaxel resistance | Diagnosis | Peng [88] | 2018 |
| miR-30c | MTA1 | A549 and H460 cell lines | Increased Paclitaxel sensitivity | Diagnosis | Lu [97] | 2017 |
| miR- 137 | NUCKS1 |
50 T 50N A549, A549/PTX and A549/CDDP cell lines Xenograft model |
Increased Paclitaxel sensitivity | Diagnosis and prognosis | Shen [104] | 2016 |
| Structural factors | ||||||
| miR-200c | CTSL | A549 and A549/TAX cell lines | Increased Paclitaxel sensitivity | Diagnosis | Zhao [114] | 2018 |
| miR-421 | KEAP1 |
129 T 129N 10 T serum 10N serum A549, H358, H1650, H460, and H1975 cell lines Xenograft model |
Increased Paclitaxel resistance | Diagnosis and prognosis | Duan [119] | 2019 |
| miR-223 | FBW7 | A549, NCI-H358, NCI-H1299 and HCC827 cell lines | Increased Doxorubicin resistance | Diagnosis | Li [126] | 2016 |
| miR-490-5p | UBE2T |
50 T (20R 30S) 50N H1299 and A549 cell lines Xenograft model |
Increased Paclitaxel sensitivity | Diagnosis | Wang [129] | 2023 |
| miR-558 | MMP1/MMP17 |
46 T 46N A549, H1299, H358, and PC9 cell lines |
Increased Paclitaxel resistance | Diagnosis | Li [131] | 2021 |
| miR-197-3p | p120-ctn |
326 T 326N A549, H1299, H460 and SPC-A-1 cell lines Xenograft model |
Increased Paclitaxel and Doxorubicin sensitivity | Diagnosis and prognosis | Yang [137] | 2019 |
| miR-708-5p | COX-2/mPGES-1 | A549, A549-ER, and A549-PR cell lines | Increased Paclitaxel sensitivity | Diagnosis | Monteleone [143] | 2020 |
| miR-486-3p | CRABP2 |
65 T (30R 35S) 65N A549 and H1299 cell lines Xenograft model |
Increased Paclitaxel sensitivity | Diagnosis | Wu [144] | 2022 |
| miR-526b-5p | GRK5 |
65 T 65N A549, H3122, H1975, and H2342 cell lines Xenograft model |
Increased Paclitaxel sensitivity | Diagnosis | Liu [146] | 2021 |
| mR-299-3p | ABCE1 |
20 T 20N NCI-H69 cell line |
Increased Doxorubicin sensitivity | Diagnosis | Zheng [149] | 2015 |
| Apoptosis and DNA repair | ||||||
| miR-1273f | MDM2 |
20 T 20N A549 and A549/Taxol cell lines Xenograft model |
Increased Paclitaxel sensitivity | Diagnosis and prognosis | Xu [153] | 2021 |
| miR-107 | Bcl-w |
A549 and HEK 293 T cell lines Xenograft model |
Increased Paclitaxel sensitivity | Diagnosis | Lu [161] | 2017 |
| miR-30a-5p | BCL-2 |
94 T 94N A549, H460, A549/PR, and H460/PR cell lines Xenograft model |
Increased Paclitaxel sensitivity | Diagnosis and prognosis | Xu [162] | 2017 |
| miR-7-5p | PARP1 | H69, H69AR, and H446AR | Increased Doxorubicin sensitivity | Diagnosis | Lai [167] | 2019 |
| miR-195 | CHEK1 |
57 T 57N H1155, H1993 and H358 cell lines Xenograft model |
Increased Paclitaxel sensitivity | Diagnosis and prognosis | Yu [169] | 2018 |
| miR-433-3p | CHEK1 |
41 T 41N A549, H1299, A549/PTX and H1299/PTX cell lines |
Increased Paclitaxel sensitivity | Diagnosis | Jin [170] | 2022 |
| Autophagy and drug efflux | ||||||
| miR-17-5p | Beclin1 | A549, H596, A549-T24, and H596-TxR cell lines | Increased Paclitaxel sensitivity | Diagnosis | Chatterjee [180] | 2014 |
| miR-199a-5p | ATG5 | A549, H1299, H661, H522, H1944, and A549/T cell lines | Increased Paclitaxel resistance | Diagnosis | Zeng [183] | 2021 |
| miR-155 | AKT/ERK | A549 and A549/dox cell lines | Increased Doxorubicin resistance | Diagnosis | Lv [189] | 2016 |
*Tumor (T) and normal (N) tissues